Republic of the Philippines

CEBU NORMAL UNIVERSITY

College of Nursing
Center of Excellence (COE) │Level IV Re-Accredited (AACCUP)
Telephone No.: (032) 254 4837
Email: cn@cnu.edu.ph / secretary@cnunursing.org
Website: www.cnu.edu.ph

DRUG STUDY

Patient’s Initials: JA Date of Admission: April 12, 2021 Diagnosis: Gangrenous wound @R Leg
Age: 74 Height/Weight: 5’2 ft, 60kg Clinical Intervention:
Sex: FEMALE Ward: SP Room 2 Bed No.: 2 Name of Physician: Dr.Nazareno
Mechanism of
Name of Drug Classification Indication Contraindication Side Effects Nursing Responsibilities
Action
Generic Name Therapeutic Cilostazol and General Indication Hypersensitivity to Before:
Cilostazol Classification: several of its Indicated for the cilostazol. HF of Frequent (34%–  Baseline assessment
Antiplatelet metabolites are alleviation of any severity. 10%): Headache, Assess CBC (esp.
Trade Name cyclic AMP (cAMP) symptoms of diarrhea, platelet count), BMP,
Pletal Pharmacologic phosphodiesterase intermittent Cautions: palpitations, LFT before treatment
Classification: III inhibitors (PDE III claudication (pain Hemostatic dizziness, and periodically during
Dosage: platelet- inhibitors), in the legs that disorders or active pharyngitis. treatment.
Maximum aggregation inhibiting occurs with walking bleeding (bleeding Occasional (7%–  Assess walking
a inhibitors  phosphodiesterase and disappears peptic ulcer, 3%): Nausea, distance prior to
Minimum activity and with rest). intracranial rhinitis, back pain, initiation.
a Pregnancy suppressing cAMP bleeding). Severe peripheral edema,
Patient’s Dose Category degradation with a Patient’s Indication underlying heart dyspepsia, During
100 mg/tab BID PO C resultant increase Reduce disease, abdominal pain,
pc in cAMP in intermittent thrombocytopenia, tachycardia, cough,  Intervention/evaluatio
platelets and blood claudication. pts receiving other flatulence, myalgia. n Monitor for
Form vessels, leading to platelet Rare (2%–1%): Leg improvement of
Tablet inhibition of aggregation cramps, symptoms (e.g.,
platelet inhibitors, paresthesia, rash, improved walking
Availability: aggregation and moderate to severe vomiting. distance).
Tablets: 50 mg, 100 vasodilation. hepatic Adverse  Monitor lab tests
mg. impairment, severe effects/toxic periodically.
Absorption
renal impairment. reactions:  Monitor for bleeding
Route: Onset: 2-12 weeks Overdose noted as events, cardiovascular
PO severe headache, toxicity, or lesions.
Distribution diarrhea,
Protein bound: 95- hypotension, After
98% (especially cardiac  Patient/family teaching
albumin) arrhythmias. May  Take on an empty
increase risk of stomach (at least 30
Metabolism endocardial min before or 2 hrs
Metabolized by hemorrhage, after meals).
CYP3A4 (major), fibrosis of left  Do not take with
CYP2C19 ventricle, intimal grapefruit products.
Metabolites: 4'- thickening of  Report severe
trans-hydroxy- coronary artery bleeding of any kind.
cilostazol, 3,4-
dehydro-cilostazol
Elimination
Half-life: 11-13 hr
Dialyzable: No
Excretion: Urine
(74%), feces (20%)

Source:
Kizior, R.J., Hodgson, K. J. (2019). Saunders Nursing Drug Handbook. St. Louis, Missouri: Elsevier.
Cilostazol: Medlineplus drug information. (n.d.). Retrieved April 12, 2021, from https://medlineplus.gov/druginfo/meds/a601038.html#:~:text=Cilostazol%20is
%20in%20a%20class,blood%20flow%20to%20the%20legs.